How effective is Jisandai (Bingtonsha) in treating hepatitis C? In-depth analysis

Epclusa, this product is composed of sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir) is a powerful combination drug that is a broad-spectrum antiviral drug specially designed for patients with hepatitis C (HCV). It is effective against all major hepatitis C virus genotypes, and its excellent efficacy and safety have been fully demonstrated in numerous clinical trials.

Judging from the clinical trial data, the performance of Jisandai (Bingtonsha) is excellent. Taking the ASTRAL-1 study as an example, for patients with hepatitis C 1 infection, after 12weeks of Jisandai (bingtonsa)< span> treatment, up to 96% of patients achieved sustained virological response (SVR), that is, the virus test is still negative 6 months after the end of treatment. This data fully proves the significant therapeutic effect of Jisanda (Bingtonsha) on type 1 hepatitis C.

Not only that, in the ASTRAL-2 and ASTRAL-3 studies, Jisandai (Bingtonsha) has also shown a highly effective therapeutic effect on patients with hepatitis C type 2 and type 3. Among patients who received 12 weeks of treatment, 94% to 98% pan> patients achieved SVR. This data once again confirms the broad efficacy of Jisanda (Bingtonsha) against different genotypes of hepatitis C virus.

For patients with liver cirrhosis, Jisandai (Bingtonsha) has also demonstrated its powerful therapeutic capabilities. ASTRAL-4The study showed that among patients with moderate to severe cirrhosis who received 12weeksGisanda (Bingtonsa) 93%of patients achieved SVR. This result fully illustrates the high efficacy of Jisanda (Bingtonsa) in patients with liver cirrhosis, and brings new treatment hope to hepatitis C patients with liver cirrhosis.

In addition to its remarkable efficacy, Jisandai (Bingtonsha) is also highly praised for its safety and tolerability. In clinical trials, most patients only experienced mild side effects, such as headache, fatigue, nausea, etc., during treatment with Gisada (Bingtonsa). These side effects are usually short-lived and can be well tolerated by most patients.

What’s more worth mentioning is that the long-term efficacy of Jisandai (Bingtonsha) is also very stable. Data show that the SVR rate of patients treated with GISANDA remains at a high level 6 months after the end of treatment, which means that most patients can maintain viral clearance for a long time after the end of treatment. This long-lasting efficacy is important for reducing viral recurrence and improving patients' long-term health.

The efficacy of Jisandai (Bingtonsha) also shows consistency in different patient groups, including HIV co-infected hepatitis C patients, patients with impaired renal function, and pregnant women (use with caution). Among these special groups, Jisandai (Bingtonsha) still shows good efficacy and safety.

In summary, Jisandai (Bingtonsha) has shown excellent results in the treatment of hepatitis C. Its high efficacy, good safety profile and stable long-term efficacy make it an important choice for the treatment of hepatitis C. For patients with hepatitis C of different genotypes, especially those with cirrhosis or other comorbidities, Jisandai (Bitongsha) is undoubtedly an effective and well-tolerated treatment option. Of course, when receiving Jisandai (Bingtonsha) treatment, patients still need to undergo regular follow-up and monitoring according to the doctor's recommendations to ensure the best effect and safety of the treatment.